Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Nektar Therapeutics (NASDAQ: NKTR) closed at $55.62 down -7.81% from its previous closing price of $60.33. In other words, the price has decreased by -$7.81 from its previous closing price. On the day, 0.96 million shares were traded. NKTR stock price reached its highest trading level at $59.39 during the session, while it also had its lowest trading level at $55.51.
Ratios:
For a deeper understanding of Nektar Therapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.61 and its Current Ratio is at 2.61.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 24, 2025, Reiterated its Buy rating but revised its target price to $120 from $6.50 previously.
On June 24, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $60 to $100.
Jefferies Upgraded its Hold to Buy on April 11, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 09 ’25 when ROBIN HOWARD W sold 6,666 shares for $46.69 per share. The transaction valued at 311,214 led to the insider holds 49,342 shares of the business.
ROBIN HOWARD W bought 6,666 shares of NKTR for $311,205 on Sep 09 ’25. On Sep 04 ’25, another insider, Zalevsky Jonathan, who serves as the Chief R&D Officer of the company, sold 1,721 shares for $33.52 each. As a result, the insider received 57,693 and left with 17,462 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 1147390464 and an Enterprise Value of 1058639040. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.12. Its current Enterprise Value per Revenue stands at 14.128 whereas that against EBITDA is -7.718.
Stock Price History:
The Beta on a monthly basis for NKTR is -1.09, which has changed by 2.1692307 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $61.15, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is 65.82%, while the 200-Day Moving Average is calculated to be 232.38%.
Shares Statistics:
For the past three months, NKTR has traded an average of 1.66M shares per day and 1325120 over the past ten days. A total of 19.02M shares are outstanding, with a floating share count of 18.60M. Insiders hold about 2.19% of the company’s shares, while institutions hold 45.71% stake in the company. Shares short for NKTR as of 1756425600 were 1116726 with a Short Ratio of 0.97, compared to 1753920000 on 1026119. Therefore, it implies a Short% of Shares Outstanding of 1116726 and a Short% of Float of 5.9899997.
Earnings Estimates
A detailed examination of Nektar Therapeutics (NKTR) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$3.12, with high estimates of -$2.28 and low estimates of -$3.68.
Analysts are recommending an EPS of between -$9.84 and -$11.76 for the fiscal current year, implying an average EPS of -$11.06. EPS for the following year is -$12.02, with 3.0 analysts recommending between -$11.6 and -$12.76.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $10.2M this quarter.It ranges from a high estimate of $13.1M to a low estimate of $6M. As of the current estimate, Nektar Therapeutics’s year-ago sales were $24.12MFor the next quarter, 7 analysts are estimating revenue of $10.68M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $8.4M.
A total of 8 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $39.6M, resulting in an average revenue estimate of $42.24M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $40.62M in the next fiscal year. The high estimate is $52M and the low estimate is $24M.
